Acute effects of l- and t-type calcium channel antagonists on cardiovascular reflexes in conscious rabbits

Clinical and Experimental Pharmacology and Physiology

Volumn 29, Issue 5-6, 2002, Pages 372-380

  Devlin, Mark G ^a   Angus, James A ^a   Wilson, Kathryn M ^a   Wright, Christine E ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Baroreflex; Bezold Jarisch like reflex; L type calcium channel; Mibefradil; Nasopharyngeal reflex; Orthostatic hypotension; T type calcium channel (+ ) verapamil

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT RECEPTOR; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL T TYPE; MIBEFRADIL; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; SCOPOLAMINE METHYL BROMIDE; SEROTONIN CREATININE SULFATE; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY POSTURE; CARDIOVASCULAR REFLEX; CONSCIOUSNESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INFUSION; FEMALE; HEAD TILTING; HEART RATE; MEAN ARTERIAL PRESSURE; NASOPHARYNX; NONHUMAN; ORTHOSTATIC HYPOTENSION; PRESSORECEPTOR REFLEX; RABBIT; REFLEX; TACHYCARDIA; VASOCONSTRICTION;

ANIMALS; BAROREFLEX; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CALCIUM CHANNELS, T-TYPE; CARDIOVASCULAR PHYSIOLOGY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HEART RATE; MIBEFRADIL; NASOPHARYNX; POSTURE; RABBITS; REFLEX; VERAPAMIL;

EID: 0036096174     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.2002.03670.x     Document Type: Article

References (47)

1. Multiple types of calcium channels and their selective modulation
2. Calcium channel diversity and neurotransmitter release: The ω-conotoxins and ω-agatoxins
3. 2+ channels in supporting hippocampal synaptic transmission
4. Differential effects of the calcium antagonist mibefradil in epicardial and intramyocardial coronary arteries
5. Classification of calcium channels and the sites of action of drugs modifying channel function
6. 2+ channel gene family
7. Pharmacology of the calcium antagonist mibefradil
8. Human vascular to cardiac tissue selectivity of L- and T-type calcium channel antagonists
9. Targetting voltage-gated calcium channels in cardiovascular therapy
10. Selective block of myocardial T-type calcium channels by mibefradil: A comparison with the 1,4-dihydropyridine amlodipine
11. 2+ channels by Ro 40-5967
12. 2+ in dog coronary arterial muscle cells by Ro 40-5967
13. Effects of the novel T-type calcium channel antagonist mibefradil on human myocardial contractility in comparison with nifedipine and verapamil
14. The acute effects of intravenously administered mibefradil, a new calcium antagonist, on the electrophysiologic characteristics of the human heart
15. Short-term hemodynamic effects of mibefradil in dogs with chronic heart failure: Comparison with diltiazem
16. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure
17. Nifedipine: Dose-related increase in mortality in patients with coronary heart disease
18. Pathophysiological mechanisms underlying the adverse effects of calcium-channel blocking drugs in patients with chronic heart failure
19. Ro 40-5967: A new nondihydropyridine calcium antagonist
20. The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses
21. Vagal and sympathetic components of the heart rate range and gain of the baroreceptor-heart rate reflex in conscious rats
22. Endogenous angiotensin II and bradykinin delay and attenuate the hypotension after N-type calcium channel blockade in conscious rabbits
23. A method for evaluating postural hypotension in conscious rabbits as a model to predict effects of drugs in man
24. ω-Conotoxin GVIA and prazosin, but not felodipine, cause postural hypotension in rabbits
25. 2+ channel blockade is amplified in experimental hypertension
26. 3 receptor-mediated cardiovascular responses in the conscious rabbit: Evidence for 5-HT release from platelets
27. Autonomic cardiovascular effects of nasal inhalation of cigarette smoke in the rabbit
28. High-performance liquid chromatography analysis of mibefradil in dog plasma and urine
29. Rapid high-pressure liquid chromatographic analysis of verapamil in blood and plasma
30. Plasma level monitoring of D,L-verapamil and three of its metabolites by reversed-phase high-performance liquid chromatography
31. Vascular amplifier properties in renovascular hypertension in conscious rabbits. Hindquarter responses to constrictor and dilator stimuli
32. Repeated measurements and multiple comparisons in cardiovascular research
33. Cardiovascular action of verapamil in the dog with particular reference to myocardial contractility and atrioventricular conduction
34. Effects of the calcium channel blockers, diltiazem and Ro 40-5967, on systemic haemodynamics and plasma noradrenaline levels in conscious dogs with pacing-induced heart failure
35. Mibefradil- and ω-conotoxin GVIA-induced inhibition of noradrenaline release from the sympathetic nerves of the human heart
36. i in human cerebral synaptosomes
37. Cardiovascular care with the new T-type calcium channel antagonist: Possible role of attendant sympathetic nervous system inhibition
38. Verapamil concentrations in cerebrospinal fluid after oral administration
39. Individual and combined actions of calcium, sodium and potassium ions on baroreceptors in the rat
40. Role of trigeminal, olfactory, carotid sinus and aortic nerves in the respiratory and circulatory response to nasal inhalation of cigarette smoke and other irritants in the rabbit
41. 2+ channel blockade with ω-conotoxin GVIA in conscious normotensive and hypertensive rabbits
42. Cardiovascular and autonomic effects of ω-conotoxins MVIIA and CVID in conscious rabbits and isolated tissue assays
43. Adverse effects associated with the intrathecal administration of ziconotide
44. Calcium channel blockers in heart failure
45. Anti-anginal and anti-ischemic effects of mibefradil, a new T-type calcium channel antagonist
46. Potential cardioprotective effect of mibefradil in the long-term treatment of hypertension